15 completed, 14 terminated, 8 recruiting, 5 withdrawn. 48 Phase 1, 13 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 48 | Completed 15, Terminated 14, Recruiting 8, Withdrawn 5, Active not recruiting 4, Unknown 2 |
| Phase 2 | 13 | Recruiting 4, Terminated 4, Completed 3, Unknown 1, Withdrawn 1 |
Follow Ovarian Carcinoma: new trials by email Literature Review of Ovarian Carcinoma trials Research Report on Ovarian Carcinoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| DT2216 + Paclitaxel in Platinum-Resistant Ovarian Cancer DT2216, Paclitaxel - Ovarian Cancer, Ovarian Carcinoma | Phase 1 | Recruiting | Elizabeth Stover, MD, PhD | 30 | 2025-09-22 | 2026-09-11 |
| Determining the Biodistribution of an Imaging Tracer (68Ga-FAPi-46) in Patients With Solid Tumors or Hematologic Cancers Computed Tomography, Fludeoxyglucose F-18, Gallium Ga 68 FAPi-46 - Anal Carcinoma, Bladder Carcinoma | Phase 1 | Active not recruiting | Jonsson Comprehensive Cancer Center | 30 | 2025-08-01 | 2026-10-20 |
| A Phase 1 Study of ATV-1601 in Patients With Advanced Cancer That Have AKT1 E17K Mutations ATV-1601, ATV-1601 + Fulvestrant - Advanced Solid Tumors, Breast Cancer | Phase 1 | Active not recruiting | Atavistik Bio, Inc | 134 | 2025-07-29 | 2026-08-07 |
| Sequential CD146 and GPC3 CAR-T Cell Therapy in Advanced Ovarian Cancer GPC3 CD146 CAR-T cells - Ovarian Cancer, Ovarian Carcinoma | Phase 1 / Phase 2 | Recruiting | Essen Biotech | 80 | 2025-04-29 | 2025-07-16 |
| Intraperitoneal Cytokine-Induced Memory Like (CIML) Natural Killer (NK) Cells in Recurrent Ovarian Cancer Cytokine-Induced Memory-like Natural Killer Cells, Interleukin 2 - Platinum-resistant Ovarian Cancer, Recurrent Ovary Cancer | Phase 1 | Recruiting | Dana-Farber Cancer Institute | 18 | 2024-10-09 | 2026-06-16 |
| A Study With NKT3964 for Adults With Advanced/Metastatic Solid Tumors NKT3964, Paclitaxel, Doxorubicin - Solid Tumor, Advanced Solid Tumor | Phase 1 | Recruiting | NiKang Therapeutics, Inc. | 238 | 2024-09-19 | 2026-11-05 |
| A Study to Learn About How Different Amounts of the Study Medicine PF-07826390 Act in the Body of People With Cancer When Taken Alone or With Other Anti-cancer Medicines. PF-07826390, sasanlimab, SOC (anti-PD-1 + platinum -based chemo) - Neoplasms, Non-small-cell Lung Cancer | Phase 1 | Terminated | Pfizer | 10 | 2024-09-06 | 2026-02-23 |
| NM32-2668 in Adult Patients With Selected Advanced Solid Tumors NM32-2668 - Ovarian Carcinoma, Fallopian Tube Carcinoma | Phase 1 | Terminated | Numab Therapeutics AG | 11 | 2024-05-01 | 2025-07-23 |
| A Study With NKT3447 for Adults With Advanced/Metastatic Solid Tumors NKT3447 - Solid Tumor, Solid Tumor, Adult | Phase 1 | Terminated | NiKang Therapeutics, Inc. | 23 | 2024-02-23 | 2025-09-25 |
| A Study of PF-07820435 as a Single Agent and in Combination in Participants With Advanced Solid Tumors PF-07820435, Sasanlimab - Neoplasms, Non-small-cell Lung Cancer | Phase 1 | Terminated | Pfizer | 9 | 2024-02-08 | 2025-09-17 |
| Intraperitoneal LSTA1 in CRS-HIPEC CRS-HIPEC + LSTA1, CRS-HIPEC alone - Colorectal Cancer, Ovarian Carcinoma | Phase 1 | Withdrawn | University of California, San Diego | 2023-11-30 | 2024-08-20 | |
| PEP-DC and OC-DC Vaccine in High Grade Serous Ovarian Carcinoma PEP-DC1, OC-DC, PEP-DC2 - Ovarian Carcinoma | Phase 1 / Phase 2 | Withdrawn | Centre Hospitalier Universitaire Vaudois | 2023-08-01 | 2025-03-05 | |
| NEOadjuvant Dendritic Cell Vaccination for Ovarian Cancer XP-DC vaccinations - Epithelial Ovarian Cancer, Ovarian Carcinoma | Phase 1 / Phase 2 | Recruiting | Radboud University Medical Center | 10 | 2023-03-17 | 2025-11-18 |
| AMT-151 in Patients With Selected Advanced Solid Tumours AMT-151 - Advanced Solid Tumor, Advanced Cancer | Phase 1 | Unknown | Multitude Therapeutics Inc. | 30 | 2023-01-25 | 2023-10-19 |
| Pamiparib Plus Surufatinib in Patients With Platinum-resistant Ovarian Cancer Pamiparib, Surufatinib - Ovarian Cancer, Ovarian Carcinoma | Phase 1 / Phase 2 | Completed | Sun Yat-sen University | 29 | 2022-09-22 | 2026-03-10 |
| Study of Maplirpacept (PF-07901801) in Combination With PLD in Patients With Platinum-Resistant Ovarian Cancer maplirpacept (PF-07901801), Pegylated Liposomal Doxorubicin (PLD) - Ovarian Cancer, Ovarian Neoplasms | Phase 1 / Phase 2 | Terminated | Pfizer | 10 | 2022-08-01 | 2024-11-19 |
| Phase I/II Study of Autologous T Cells to Express T-Cell Receptors (TCRs) in Subjects With Solid Tumors Neoantigen specific TCR-T cell drug product, Aldesleukin (IL-2) - Gynecologic Cancer, Colorectal Cancer | Phase 1 / Phase 2 | Terminated | Alaunos Therapeutics | 8 | 2022-04-04 | 2025-11-10 |
| A Study of STRO-002, an Anti-Folate Receptor Alpha Antibody Drug Conjugate, in Combination With Bevacizumab in Epithelial Ovarian Cancer STRO-002, Bevacizumab - Ovarian Cancer, Ovarian Carcinoma | Phase 1 | Terminated | Sutro Biopharma, Inc. | 58 | 2022-03-22 | 2025-09-22 |
| Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors Biospecimen Collection, Dual X-ray Absorptiometry, Tegavivint - Colorectal Carcinoma, Endometrial Carcinoma | Phase 1 / Phase 2 | Recruiting | Children's Oncology Group | 147 | 2021-11-08 | 2026-08-25 |
| A Study to Evaluate ELU001 in Patients With Solid Tumors That Overexpress Folate Receptor Alpha (FRĪ±) ELU001 - Ovarian Cancer, Ovarian Neoplasms | Phase 1 / Phase 2 | Terminated | Elucida Oncology | 79 | 2021-09-13 | 2024-08-07 |
Showing 20 of 48. Sign in to see all of them.
Ovarian Neoplasms (48) · Fallopian Tube Neoplasms (15) · Endometrial Neoplasms (13) · Breast Neoplasms (11) · Colorectal Neoplasms (10) · Triple Negative Breast Neoplasms (10) · Carcinoma, Non-Small-Cell Lung (9) · Melanoma (9) · Neoplasm Metastasis (8) · Carcinoma, Transitional Cell (7) · Neoplasms (7) · Carcinoma, Renal Cell (6) · Squamous Cell Carcinoma of Head and Neck (6) · Prostatic Neoplasms (5) · Sarcoma (5)
Adnexal Diseases (48) · Endocrine Gland Neoplasms (48) · Endocrine System Diseases (48) · Female Urogenital Diseases (48) · Female Urogenital Diseases and Pregnancy Complications (48) · Genital Diseases (48) · Genital Diseases, Female (48) · Gonadal Disorders (48) · Urogenital Diseases (48) · Genital Neoplasms, Female (47) · Neoplasms by Site (47) · Ovarian Diseases (47) · Urogenital Neoplasms (47) · Neoplasms (41) · Neoplasms by Histologic Type (23)
Paclitaxel (9) · Carboplatin (4) · Taxes (4) · Bevacizumab (3) · Cyclophosphamide (3) · veliparib (3) · Docetaxel (2) · Doxorubicin (2) · Fluorodeoxyglucose F18 (2) · Hyperthermic Intraperitoneal Chemotherapy (2) · Interleukin-2 (2) · Magnetic Resonance Spectroscopy (2) · 1,2-diaminocyclohexaneplatinum II citrate (1) · 1-dodecylpyridoxal (1) · Absorptiometry, Photon (1)
National Cancer Institute (NCI) (4) · Pfizer (4) · M.D. Anderson Cancer Center (3) · NiKang Therapeutics, Inc. (2) · Numab Therapeutics AG (2) · Sutro Biopharma, Inc. (2) · Abramson Cancer Center at Penn Medicine (1) · Alaunos Therapeutics (1) · Atavistik Bio, Inc (1) · Avacta Life Sciences Ltd (1) · Centre Hospitalier Universitaire Vaudois (1) · Children's Oncology Group (1) · Dana-Farber Cancer Institute (1) · Elizabeth Stover, MD, PhD (1) · Elucida Oncology (1)
United States (36) · China (4) · Spain (4) · France (3) · Belgium (2) · Germany (2) · Australia (1) · India (1) · Japan (1) · Netherlands (1) · Puerto Rico (1) · Singapore (1) · South Korea (1) · Switzerland (1) · Taiwan (1)
Aaron H Wolfson, MD (1) · Anthony Elias, MD (1) · Apostolos Sarivalasis, MD (1) · Arturo Molina, MD (1) · Aung Naing (1) · Aung Naing, MD (1) · Boris Kobrinsky, M.D. (1) · C. William Helm, MD (1) · Catherine Shannon (1) · Chris Twelves, MD (1) · Cristina Sessa, MD (1) · Elizabeth Stover, MD, PhD (1) · Elke Jager, MD (1)
PMID 36459691, PMID 22847809, PMID 28275119, PMID 29995186, PMID 31708167, PMID 33610319, PMID 33909232, PMID 34562230, PMID 34965890, PMID 35537408, PMID 37129197, PMID 37735588, PMID 39208372, PMID 39816915, PMID 39945382, PMID 41213670, PMID 41424175
P30CA016672 (2), P30CA047904 (2), U01CA062505 (2), U01CA099168 (2), UM1CA186690 (2), UM1CA186716 (2), UM1CA186717 (2), N01CM00100 (1), P30CA016056 (1), R01CA249329 (1), U01CA062461 (1), U01CA062490 (1), U01CA062502 (1), U01CA069856 (1), U01CA070095 (1)